Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

计划入组 627 人 · 首次发布于 2006 年 10 月 23 日

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

计划入组 40 人 · 首次发布于 2008 年 12 月 3 日

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

计划入组 32 人 · 首次发布于 2009 年 3 月 25 日

FCR-002

Lumiliximab

ALTERNATIVES FOR GIRLS

United States

Institutt For Energiteknikk

Sweden

MCR Health, Inc.

United States

AMPLIFY Trial: Acalabrutinib and Venetoclax Show Promise in Treatment-Naive CLL

ERADIC Trial: Ibrutinib and Venetoclax Combination Shows Superiority in CLL

MRD-Guided Ibrutinib-Venetoclax Therapy Shows Superior Outcomes in CLL Treatment: FLAIR Trial Results